CD274 and neoplasm: In the group that received sequential combined therapy of 177Lu-EB-RGD and anti-PD-L1 mAb (Group E), a slightly less profound therapeutic efficacy was observed than in the group that received concurrent combined therapy (Group D), with the tumor volumes in Group E being slightly larger than those in Group D from day 8 after treatment (P = 0.007), but still significantly smaller than those in Groups B and C from day 16 until the end of the study (Figure 4C; purple line).